Image Source: LinkedIn
Strides Pharma Science Ltd has announced a strategic partnership with Kenox Pharmaceuticals to expand its nasal spray portfolio for the U.S. market, marking a significant step in its push toward complex generics and specialty formulations. The collaboration is aimed at developing, manufacturing, and commercializing a range of nasal spray products, leveraging Strides’ U.S. FDA-approved facility and Kenox’s formulation expertise.
This move aligns with Strides’ broader strategy to diversify its product offerings in regulated markets, particularly in segments with high entry barriers and strong demand for alternative drug delivery systems.
Key Highlights
-
Strides Pharma partners with Kenox Pharmaceuticals to co-develop nasal sprays for the U.S. market
-
Products will be manufactured at Strides’ Chestnut Ridge facility in New York, acquired from Endo Inc. in 2021
-
The portfolio includes four nasal spray products targeting a combined market size of over $400 million
-
Kenox will lead formulation development while Strides handles manufacturing and commercialization
-
The partnership strengthens Strides’ presence in the respiratory and ENT therapeutic segments
The Chestnut Ridge facility is equipped with advanced capabilities for unit-dose and multi-dose nasal spray manufacturing, including for controlled substances. This infrastructure gives Strides a competitive edge in delivering high-quality, complex formulations that meet stringent U.S. regulatory standards.
Kenox Pharmaceuticals, known for its work in inhalation and parenteral drug development, brings deep formulation expertise to the table. The collaboration will focus on products that address chronic rhinitis, allergic conditions, and other upper respiratory disorders, with potential expansion into emergency-use nasal therapies.
Strides has been actively expanding its U.S. footprint, with recent launches in injectables, soft gel capsules, and topical formulations. The nasal spray initiative complements its strategy to build a robust specialty portfolio and improve margins through differentiated products.
The partnership also reflects the growing demand for non-invasive drug delivery systems in the U.S., driven by patient preference, ease of administration, and rapid onset of action. Nasal sprays are increasingly used not only for local treatment but also for systemic delivery of drugs, including pain management and hormone therapies.
Strides expects the first product filings from this collaboration to begin in FY26, with commercial rollouts targeted for FY27, subject to regulatory approvals. The company has indicated that the partnership will be margin-accretive and contribute meaningfully to its U.S. revenue base over the next three years.
Sources: Express Pharma, OINDP News, Strides Corporate Presentation – Feb 2024
Advertisement
Advertisement
